Genome-wide nucleosome mapping in multiple myeloma

por Small, Eliza C, Zhang, Quanwei, Popovic, Relja, Hua, Youjia, Wang, Ji-Ping, Licht, Jonathan D
Publicado 2013

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1

por Kumar, Krishan, Raza, Sania S., Knab, Lawrence M., Chow, Christina R., Kwok, Benjamin, Bentrem, David J., Popovic, Relja, Ebine, Kazumi, Licht, Jonathan D., Munshi, Hidayatullah G.
Publicado 2015

The Histone Methyltransferase MMSET/WHSC1 Activates TWIST1 to Promote an Epithelial-Mesenchymal Transition and Invasive Properties of Prostate Cancer

por Ezponda, Teresa, Popovic, Relja, Shah, Mrinal Y., Martinez-Garcia, Eva, Zheng, Yupeng, Min, Dong-Joon, Will, Christine, Neri, Antonino, Kelleher, Neil L., Yu, Jindan, Licht, Jonathan D.
Publicado 2012

A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid...

por Borthakur, Gautam, Odenike, Olatoyosi, Aldoss, Ibrahim, Rizzieri, David A., Prebet, Thomas, Chen, Chris, Popovic, Relja, Modi, Dimple A., Joshi, Rujuta H., Wolff, Johannes E., Jonas, Brian A.
Publicado 2021

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy

por Handunnetti, Sasanka, Anderson, Mary Ann, Roberts, Andrew W., Davids, Matthew S., Ma, Shuo, Boyer, Michelle, Arzt, Jennifer, Masud, Abdullah Al, Popovic, Relja, Jacobson, Amanda, Kim, Su Y., Seymour, John F.
Publicado 2021

Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia

por Chyla, Brenda, Daver, Naval, Doyle, Kelly, McKeegan, Evelyn, Huang, Xin, Ruvolo, Vivian, Wang, Zixing, Chen, Ken, Souers, Andrew, Leverson, Joel, Potluri, Jalaja, Boghaert, Erwin, Bhathena, Anahita, Konopleva, Marina, Popovic, Relja
Publicado 2018

MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents

por Shah, Mrinal Y., Martinez-Garcia, Eva, Phillip, Jude M., Chambliss, Allison B., Popovic, Relja, Ezponda, Teresa, Small, Eliza C., Will, Christine, Phillip, Madonna P., Neri, Paola, Bahlis, Nizar J., Wirtz, Denis, Licht, Jonathan D.
Publicado 2016

MMSET dysregulates gene expression in myeloma through global and focal changes in H3K36 and H3K27 methylation

por Popovic, Relja, Martinez-Garcia, Eva, Zhang, Quanwei, Ezponda, Teresa, Shah, Mrinal Y, Zhang, Yupeng, Jiang, Yanwen, Will, Christine M, Small, Eliza C, Bulic, Marinka, Elemento, Olivier, Kelleher, Neil, Kath, William, Wang, Ji-Ping, Licht, Jonathan D
Publicado 2013

Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy

por Popovic, Relja, Dunbar, Fengjiao, Lu, Charles, Robinson, Kenneth, Quarless, Danjuma, Warder, Scott E., Mukherjee, Nabanita, Pesko, John, Souers, Andrew J., Waring, Jeffrey F., Davids, Matthew S., Tausch, Eugen, Stilgenbauer, Stephan, Ross, Jeremy A., Leverson, Joel D., Kim, Su Young, Chyla, Brenda J.
Publicado 2021

Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation

por Popovic, Relja, Martinez-Garcia, Eva, Giannopoulou, Eugenia G., Zhang, Quanwei, Zhang, Qingyang, Ezponda, Teresa, Shah, Mrinal Y., Zheng, Yupeng, Will, Christine M., Small, Eliza C., Hua, Youjia, Bulic, Marinka, Jiang, Yanwen, Carrara, Matteo, Calogero, Raffaele A., Kath, William L., Kelleher, Neil L., Wang, Ji-Ping, Elemento, Olivier, Licht, Jonathan D.
Publicado 2014

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

por Wei, Andrew H., Strickland, Stephen A., Hou, Jing-Zhou, Fiedler, Walter, Lin, Tara L., Walter, Roland B., Enjeti, Anoop, Tiong, Ing Soo, Savona, Michael, Lee, Sangmin, Chyla, Brenda, Popovic, Relja, Salem, Ahmed Hamed, Agarwal, Suresh, Xu, Tu, Fakouhi, Kaffa M., Humerickhouse, Rod, Hong, Wan-Jen, Hayslip, John, Roboz, Gail J.
Publicado 2019

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

por Zhang, Qi, Riley-Gillis, Bridget, Han, Lina, Jia, Yannan, Lodi, Alessia, Zhang, Haijiao, Ganesan, Saravanan, Pan, Rongqing, Konoplev, Sergej N., Sweeney, Shannon R., Ryan, Jeremy A., Jitkova, Yulia, Dunner, Kenneth, Grosskurth, Shaun E., Vijay, Priyanka, Ghosh, Sujana, Lu, Charles, Ma, Wencai, Kurtz, Stephen, Ruvolo, Vivian R., Ma, Helen, Weng, Connie C., Ramage, Cassandra L., Baran, Natalia, Shi, Ce, Cai, Tianyu, Davis, Richard Eric, Battula, Venkata L., Mi, Yingchang, Wang, Jing, DiNardo, Courtney D., Andreeff, Michael, Tyner, Jeffery W., Schimmer, Aaron, Letai, Anthony, Padua, Rose Ann, Bueso-Ramos, Carlos E., Tiziani, Stefano, Leverson, Joel, Popovic, Relja, Konopleva, Marina
Publicado 2022

Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

por Zhang, Qi, Riley-Gillis, Bridget, Han, Lina, Jia, Yannan, Lodi, Alessia, Zhang, Haijiao, Ganesan, Saravanan, Pan, Rongqing, Konoplev, Sergej N., Sweeney, Shannon R., Ryan, Jeremy A., Jitkova, Yulia, Dunner, Kenneth, Grosskurth, Shaun E., Vijay, Priyanka, Ghosh, Sujana, Lu, Charles, Ma, Wencai, Kurtz, Stephen, Ruvolo, Vivian R., Ma, Helen, Weng, Connie C., Ramage, Cassandra L., Baran, Natalia, Shi, Ce, Cai, Tianyu, Davis, Richard Eric, Battula, Venkata L., Mi, Yingchang, Wang, Jing, DiNardo, Courtney D., Andreeff, Michael, Tyner, Jeffery W., Schimmer, Aaron, Letai, Anthony, Padua, Rose Ann, Bueso-Ramos, Carlos E., Tiziani, Stefano, Leverson, Joel, Popovic, Relja, Konopleva, Marina
Publicado 2022